Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2004 Jun 7;85(4):12–17. doi: 10.1016/0002-9343(88)90356-7

New perspectives on the pathogenesis of rheumatoid arthritis

Nathan J Zvaifler 1,
PMCID: PMC7119386  PMID: 3052052

Abstract

In the pathogenesis of rheumatoid arthritis, locally produced antibodies complex with an inciting antigen, yet to be identified, within the joint and activate the complement system, resulting in articular inflammation mediated primarily by polymorphonuclear leukocytes and their products. Chronic inflammatory cells then produce soluble factors that induce both tissue destruction and inflammation. A major issue is how and why apparently normal immune responses in the acute stage progress to chronic inflammation in subsequent months to years. Although it is often assumed that the initial etiologic agent, persisting in the joint or at an extra-articular site, is responsible for continued synovitis, this need not be the case. It is possible that once the inciting agent is cleared from the joint through a normal immune response, the presence of activated cells rich in surface class II histocompatibility (Ia) antigens could, under the influence of multiple genetic or environmental factors, become the target of autoimmune attack. Alternatively, the process might result from the interactions of synovial lining cells and their products with T cells assuming a secondary role. Further research into the relative contributions of soluble products, T helper and suppressor subsets, synoviocytes, and antigen determine which model is correct.

References

  • 1.Condemi JJ. The autoimmune diseases. JAMA. 1987;258:2920–2929. [PubMed] [Google Scholar]
  • 2.Firestein GS, Tsai V, Zvaifler NJ. Cellular immunity in the joints of patients with rheumatoid arthritis and other forms of chronic synovitis. Rheum Dis Clinics NA. 1987;13:191–213. [PubMed] [Google Scholar]
  • 3.Fassbender HG. Rheumatoid arthritis. In: Fassbender HG, editor. Pathology of rheumatic disease. Springer-Verlag; New York: 1975. p. 5. [Google Scholar]
  • 4.Kulka JP, Bocking D, Ropes MW. Early joint lesions of rheumatoid arthritis. Arch Pathol. 1955;59:129–149. [PubMed] [Google Scholar]
  • 5.Schumacher HR, Kitridou RC. A clinicopathologic study during the first month of disease. 2nd ed. Vol. 15. 1972. Synovitis of recent onset; pp. 465–485. (Arthritis Rheum). [DOI] [PubMed] [Google Scholar]
  • 6.Klareskog L, Forsum U, Wigren A, Wigzell H. Relationships between HLA-DR-expressing cells and T lymphocytes of different subsets in rheumatoid synovial tissue. Scand J Immunol. 1982;15:501–507. doi: 10.1111/j.1365-3083.1982.tb00676.x. [DOI] [PubMed] [Google Scholar]
  • 7.Ishikawa H, Ziff M. Electron microscopic observations of immunoreactive cells in the rheumatoid synovial membrane. Arthritis Rheum. 1976;19:1–14. doi: 10.1002/art.1780190101. [DOI] [PubMed] [Google Scholar]
  • 8.Knottinen YT, Reitamo S, Ranki A. Characterization of the immunocompetent cells of rheumatoid synovium from tissue sections and eluates. Arthritis Rheum. 1983;24:71–79. doi: 10.1002/art.1780240112. [DOI] [PubMed] [Google Scholar]
  • 9.Burmester GR, Jahn B, Gramatzki M. Activated T cells in vivo and in vitro: divergents and expression of Tac and Ia antigens in the nonblastoid small T cells of inflammation and normal T cells activated in vitro. J Immunol. 1984;133:1230–1234. [PubMed] [Google Scholar]
  • 10.Fox RI, Fong S, Sabharwal U. Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis. J Immunol. 1982;128:352–354. [PubMed] [Google Scholar]
  • 11.Cush JJ, Lipsky P. The immunopathogenesis of rheumatoid arthritis: the role of cytokines in chronic inflammation. Clin Aspects Autoimmunity. 1987;1:2–13. [Google Scholar]
  • 12.Steere AC, Duray H, Butcher EC. Spirochetal antigens and lymphoid cell markers in Lyme synovitis: comparison with rheumatoid synovium and tonsillar lymphoid tissue. Arthritis Rheum. 1988;31:487–495. doi: 10.1002/art.1780310405. [DOI] [PubMed] [Google Scholar]
  • 13.Nathan CF, Murray HW, Wuke ME. Identification of gamma-interferon as the lymphokine which activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983;158:670–689. doi: 10.1084/jem.158.3.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Young CL, Adamson TC, Vaughan JH. Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis. Arthritis Rheum. 1984;27:32–39. doi: 10.1002/art.1780270106. [DOI] [PubMed] [Google Scholar]
  • 15.Malone D, Wahl S, Tsokos M. A relationship between peripheral blood mononuclear cell proliferation to soluble antigen and synovial tissue immunohistologic characteristic. 2nd ed. Vol. 74. 1984. Immune function in severe, active rheumatoid arthritis; pp. 1173–1185. (J Clin Invest). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kurosaaka M, Ziff M. Immunoelectron microscopic study of the distribution of T cell subsets in rheumatoid synovium. J Exp Med. 1983;158:1191–1210. doi: 10.1084/jem.158.4.1191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lalor PA, Mapp PI, Hall PA. Proliferative activity of cells in the synovium as demonstrated by monoclonal antibody, Ki67. Rheumatol Int. 1987;7:183–186. doi: 10.1007/BF00541375. [DOI] [PubMed] [Google Scholar]
  • 18.Lotz M, Tsoukas CD, Robinson CA. Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibody. J Clin Invest. 1986;78:713–721. doi: 10.1172/JCI112631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Miossec P, Kashiwado T, Ziff M. Inhibitors of interleukin-2 in rheumatoid synovial fluid. Arthritis Rheum. 1987;30:121–129. doi: 10.1002/art.1780300201. [DOI] [PubMed] [Google Scholar]
  • 20.Firestein GS, Zvaifler NJ. Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that gamma-interferon is not the primary MAF in arthritis. Arthritis Rheum. 1987;30:864–871. doi: 10.1002/art.1780300804. [DOI] [PubMed] [Google Scholar]
  • 21.Firestein GS, Xu WD, Townsend K, et al: Cytokines in chronic inflammation arthritis. I. Failure to detect T cell lymphokines (IL-2 and IL-3) and presence of CSF-1 and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med (in press). [DOI] [PMC free article] [PubMed]
  • 22.Feldman M: Regulation of HLA class II expression and its role in autoimmune disease. In: Autoimmunity and autoimmune disease (Ciba Foundation Symposium 129). Chichester, England: Wiley, 80–108. [DOI] [PubMed]
  • 23.Chiosazzi N, Fu SM, Kunkel HG. Induction of polyclonal antibody synthesis by human allogenic and autologous helper factors. J Exp Med. 1976;149:1543–1548. doi: 10.1084/jem.149.6.1543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Suzuki R, Suzuki S, Takahashi T, Kumagai K. Production of a cytokine with interleukin-3 like properties and cytokine dependent proliferation in human autologous mixed lymphocyte reaction. J Exp Med. 1986;164:1689–1699. doi: 10.1084/jem.164.5.1682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Goto M, Zvaifler NJ. Characterization of the natural killer-like lymphocytes in rheumatoid synovial fluid. J Immunol. 1985;134:1483–1486. [PubMed] [Google Scholar]
  • 26.Goto M, Zvaifler NJ. Characterization of the killer cell generated in the autologous mixed leukocyte reaction. J Exp Med. 1983;157:1309–1323. doi: 10.1084/jem.157.4.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zvaifler NJ, Steinman R, Kaplan G. Dendritic cells in synovial effusions of patients with rheumatoid arthritis. J Clin Invest. 1985;76:789–800. doi: 10.1172/JCI112036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bergroth V, Firestein GS, Zvaifler NJ. Variable class II MHC induction by gamma interferon (IFN-gamma) on normal and rheumatoid arthritis (RA) monocytes. Arthritis Rheum. 1988;31:S28. doi: 10.1002/anr.1780320904. (abstr) [DOI] [PubMed] [Google Scholar]
  • 29.Suzumura A, Lavi E, Weiss SR. Coronavirus infection induced H-2 antigen expression on oligodendrocytes and astrocytes. Science. 1986;232:991. doi: 10.1126/science.3010460. [DOI] [PubMed] [Google Scholar]
  • 30.Fontana A, Hengartner H, Weber E. Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int. 1982;2:49–53. doi: 10.1007/BF00541245. [DOI] [PubMed] [Google Scholar]
  • 31.Wood DD, Ihrie EJ, Dinarello CA, Cohen PL. Isolation of an interleukin 1-like factor from human joint effusions. Arthritis Rheum. 1983;26:975–983. doi: 10.1002/art.1780260806. [DOI] [PubMed] [Google Scholar]
  • 32.Cavender D, Haskard D, Yu C-L. Pathways to chronic inflammation in rheumatoid synovitis. Fed Proc. 1987;46:113–117. [PubMed] [Google Scholar]
  • 33.Dayer JM, de Rochemonteix B, Burrus B. Human recombinant interleukin-1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest. 1986;77:645–648. doi: 10.1172/JCI112350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Lopez-Bote JP, Bernakeu P, Marquet A. Adjuvant induced polyarthritis: synovial cell activation prior to polyarthritis onset. Arthritis Rheum. 1988;31:769–775. doi: 10.1002/art.1780310611. [DOI] [PubMed] [Google Scholar]
  • 35.Alvaro-Garcia JM, Firestein GS, Xu WD, Taetle R, Zvaifler NJ. GM-CSF is a major macrophage activating factor (MAF) in rheumatoid synovitis. Arthritis Rheum. 1988;31:S27. (abstr) [Google Scholar]

Articles from The American Journal of Medicine are provided here courtesy of Elsevier

RESOURCES